Valneva to Highlight Lyme Disease Vaccine Progress at Key Investor Conferences
Event summary
- Valneva's senior management will present at three investor conferences in June 2026, including Jefferies Global Healthcare Conference on June 3 and BNP Paribas SMID Cap Conference on June 24.
- Key topics include Valneva’s commercial-stage vaccines and its differentiated portfolio, with a focus on LB6V, the Lyme Disease vaccine candidate partnered with Pfizer.
- Pfizer reported topline Phase 3 results for LB6V demonstrating strong efficacy with no safety concerns, and is planning regulatory submissions.
- Valneva will also engage with travel medical professionals at the 10th Northern European Conference on Travel Medicine (NECTM10) in Belfast, Ireland, from June 3-5.
The big picture
Valneva's participation in key investor conferences underscores the strategic importance of its Lyme Disease vaccine candidate, LB6V, which is partnered with Pfizer. The positive Phase 3 results and upcoming regulatory submissions position LB6V as a potential first-in-class solution for a significant unmet medical need. Valneva's engagement with travel medical professionals further highlights its focus on addressing global public health threats through specialized vaccine solutions.
What we're watching
- Regulatory Progress
- The pace at which Pfizer advances LB6V through regulatory approvals will determine Valneva's commercialization timeline and revenue potential.
- Investor Sentiment
- How Valneva's presentations at investor conferences influence market perception of its vaccine portfolio and growth prospects.
- Commercial Strategy
- Whether Valneva can leverage its travel vaccine expertise to expand into other infectious disease markets.
Related topics